Strides started in 1990 with the goal of building a pharmaceutical company from India that could make a difference around the world. From humble beginnings to a global healthcare partner, our journey has been one of growth, resilience, and continuous progress.
1990
Incorporation of Strides as "Strides Pharmaceuticals Private Limited" in Bombay; began as a trading company.
1991
Shifted base to Bangalore and began building early manufacturing capabilities.
1992
First exports to Nigeria; marked the beginning of Strides’ presence in Africa.
1993
Laid groundwork for regulatory compliance and built early supplier networks.
1994
Became a public company; name changed to "Strides Pharmaceuticals Limited"; fund raising from Schroders, Venture Capital.
1995
Partnered with Pharmagel (Italy) to set up a softgel facility at KR Suresh Gardens (KRSG), in Bangalore.
1996
Acquired Remed Labs; MoU with Plama Laboratories, a Mangalore Listed entity; also initiated tablet & capsule facility at KRS Gardens.
1997
Name changed to "Strides Arcolab Limited"; to reflect joint venture with Arcolab SA, Switzerland.
1998
Commissioned first softgel facility at KRSG in Bengaluru.
1999
Revenue crossed ₹100 CR; acquired Caryl Labs and Global Remedies; entered the LATAM market via Brazil; established GCC presence through Pentagon Exim. Completed three-way merger with Plama Laboratories (specialty chemicals) and Remed Laboratories (sterile injectables).
2000
Listed on National Stock Exchange and Regional Stock Exchanges; launched domestic generics division; acquired Arcolab, Geneva.
2001
Merged Bombay Drugs & Pharma Limited (BDPL) with Strides; consolidated operations in APIs.
2002
Expanded in LATAM with acquiring stake in Solara S.A. De C.V, Infabra, and Cellofarma Ltd., set up manufacturing plants in Brazil & Mexico; Arcolab became 100% subsidiary.
2003
Entered JV with Ribbon, Italy for cephalosporins; hived off CRAMs division; began development for AIDS, TB, Malaria.
2004
Listed on Bombay Stock Exchange; partnered with Akorn, USA for sterile products; restructured LATAM holdings.
2005
Launched Star Technology and Research (STAR) Global R&D centre in Bengaluru; crossed Rs. 500 CR revenue; issued USD 40 Mn via Foreign Currency Convertible Bond.
2006
Acquired stake in Beltapharm (Italy), DHA Singapore, and Arcolab facilities in Poland; entered into Clinton Foundation AIDS supply alliance.
2007
Raised USD 100 Mn via zero-coupon bonds; acquired Grandix Pharma and Farma Plus (Norway); oncology JV with Aspen. Acquired Diaspa S.p.A, a USFDA approved fermentation facility, stake in Strides Vital Nigeria Limited, Nigeria.
2008
Revenue crossed ₹1,000 CR; signed global supply deal with GlaxoSmithKline Pharmaceuticals (GSK) for emerging markets; acquired controlling stake in Genepharm Australasia (later renamed Ascent Pharmahealth), making Strides the fourth-largest generics player in Australia.
2009
Launched critical care division ‘Ray of Life’; restructured into Pharma and Specialty; launched Starflu for H1N1.
2010
Revenue crossed ₹1,500 CR; entered oncology tie-up with Pfizer; rebranded injectable business as Agila; acquired Inbiopro entering biologics space.
2011
Divested Australia business to Watson for AUD 375 Million; expanded Agila to Malaysia; extended Pfizer licensing to emerging markets.
2012
Partnered with Gilead & Eli Lilly; raised funds from Proparco for African expansion; acquired sterile facility in Hosur, Tamil Nadu.
2013
Divested Agila to Mylan for $1.6B; declared ₹630/share dividend; rebranded biotech business as Stelis Biopharma.
2014
Merged Stelis with Inbiopro; brought in GMS Holdings as investor in Stelis; acquired branded India assets from Bafna.
2015
Merged with Shasun to form Strides Shasun; re-entered Australia through Arrow; expanded India portfolio with CNS brands from Sun Pharma and J&J; and strengthened Sub-Saharan presence via Medispan and Universal Corp., gaining a rare WHO PQ facility.
2016
Arrow signed 10-year alliance with Pharmacy Alliance; exited CRAMS UK; acquired PediaCare brand.
2017
Exited probiotics and Africa generics; demerged API business as Solara; formed JV with Vivimed for US market. Divested India Brands Business to Eris Life Sciences, including transfer of stake in Strides Healthcare Private Limited.
2018
Renamed as Strides Pharma Science Ltd; divested Strides Chemicals to Solara; partnered with ILS for Consumer Health division.
2019
Acquired Florida facility; entered China via JV; acquired Fairmed Healthcare, Switzerland.
2020
Merged Arrow, Remedies & Strides EM business; Stelis raised $195 Mn; began exports of Favipiravir during COVID.
2021
Acquired Chestnut Ridge facility, along with basket of ANDAs from Endo International Plc., USA; launched Stripiravir (Molnupiravir); partnered with MPP for global COVID drugs.
2022
Stelis received EU-GMP; Universal Kenya received WHO PQ; EMA approval for Kauliv biosimilar.
2023
Partnered with Orbicular for nasal sprays; Stelis divested Unit 3 to Syngene; consolidated South Africa operations under Trinity.
2024
Merged Strides Alathur into parent; demerged CDMO & softgel biz into OneSource.
2025
Listed OneSource on National Stock Exchange & Bombay Stock Exchange as specialty CDMO; Celebrated 35 years of Strides. Crossed ₹4,565 CR revenue & ₹802 Cr EBITDA; created ₹115 Bn+ shareholder value; reinforced global pharma position.
